Novel compound ZCJ14, a gefitinib analog, exhibited prominent anti-cancer effect among several cancer cell lines
| Autor: | Jin, Wang, Ping-Ping, Yan, Hong-Ying, Wang, Sai-Jie, Zuo, San-Qi, Zhang, Yong-Xiao, Cao, Lei, Cao |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Proteomics
Lung Neoplasms Proteome Mice Nude Antineoplastic Agents Apoptosis Gefitinib General Medicine Xenograft Model Antitumor Assays General Biochemistry Genetics and Molecular Biology ErbB Receptors Mice Drug Resistance Neoplasm Carcinoma Non-Small-Cell Lung Cell Line Tumor Animals Humans Steroids General Pharmacology Toxicology and Pharmaceutics Ubiquitins Cell Proliferation |
| Zdroj: | Life Sciences. 307:120875 |
| ISSN: | 0024-3205 |
| DOI: | 10.1016/j.lfs.2022.120875 |
| Popis: | ZCJ14, a gefitinib analog, exhibited prominent anti-cancer effect both in vitro and in vivo. The present study aims to investigate the inhibitory effects of ZCJ14 on human cancer cells, and explored its possible mechanism of action.The inhibitory effect of ZCJ14 on human-derived tumor cells in vitro was mainly measured by MTT and colony formation assays. The nude mouse xenograft models were established to figure out the inhibitory effect of ZCJ14 on solid tumors in vivo. Western blotting assays were used to detect the phosphorylation level of EGFR down-streaming proteins and the proteomic technique was used to study the proteome alterations of cancer cells triggered by ZCJ14.ZCJ14 inhibited the proliferation of A549 (lung cancer), HCT116 (colorectal cancer) and MCF-7 (breast cancer) cells in vitro with 48 h ICBased on the excellent anti-tumor effect of ZCJ14 on human tumor cell lines, it can be used as an effective anti-tumor drug candidate. In addition, the results of proteomic study in this paper can provide clues for further study of the anti-tumor mechanism of ZCJ14. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect